(3R,4S)-3-(2-Bromoacetyl)-4-Ethyl-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester

When a convergent synthesis strategy demands late-stage introduction of a chiral 3-acylpyrrolidine pharmacophore, (3R,4S)-3-(2-bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylic acid phenylmethyl ester is deployed as the electrophilic coupling partner. Production-scale campaigns conducted in glass-lined reactors with 3,000–5,000 L capacity have demonstrated consistent batch-to-batch performance when the bromoacetyl moiety is reacted with sterically hindered secondary amines under Schotten–Baumann conditions. The process window is narrow: aqueous phase pH must be maintained at 8.3 ± 0.2 using 50 wt% potassium carbonate solution, as excursions above pH 9.0 accelerate phenylmethyl ester hydrolysis beyond 2.5% per hour at 15°C. In the manufacture of an oral coagulation factor Xa inhibitor (proceeding under ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients and FDA 21 CFR Part 211 finished dose requirements), the bromoacetyl intermediate is charged at a molar ratio of 1.08–1.15 equivalents relative to the amine nucleophile. The coupling is executed in a binary tetrahydrofuran/water (3:1 v/v) mixture with nitrogen sparging to purge hydrobromic acid vapor. Post-reaction quenching with 5% aqueous sodium bisulfite destroys residual bromoacetyl species and prevents dimerization side products. Downstream processing involves phase separation, concentration of the organic layer to a target residual volume of 2.5–3.0 L/kg of product, and crystallization from methyl tert-butyl ether/n-heptane (1:4 v/v) at a cooling rate controlled to 0.25°C/min between 50°C and 5°C. The crystalline isolated product routinely exhibits differential scanning calorimetry endotherm onset at 68.5 ± 1.0°C and enantiomeric purity no less than 99.5 area% by chiral HPLC (Chiralpak AD-H, hexane/ethanol 85:15, 1.0 mL/min, 210 nm). The terminal dosage form manufactured from the final API is an immediate-release film-coated tablet containing 25 mg or 50 mg of the tosylate salt, with dissolution compliance tested per USP 〈711〉 Apparatus 2 at 75 rpm in 0.01 N HCl. Residual palladium from an upstream hydrogenolysis step must be controlled below 10 ppm per ICH Q3D Elemental Impurities Guideline, and the phenylmethyl ester-derived benzyl alcohol byproduct is monitored by GC headspace analysis with a reporting threshold of ≤ 500 ppm.

What Limits Enantiomeric Excess in Pd-Catalyzed Allylic Substitutions Using This Scaffold?

A distinct commercial trajectory converts the bromoacetyl intermediate into a family of P,N-bidentate ligands for palladium-catalyzed asymmetric allylic alkylation (AAA), a transformation used by contract manufacturing organizations to produce nonracemic α-substituted ketone intermediates for cardiovascular drugs. The (3R,4S)-4-ethylpyrrolidine framework imposes a defined dihedral angle on the chelating arm, and pilot-scale hydrogenation data from a 500-L Hastelloy autoclave indicate that enantioselectivity in the subsequent AAA step is acutely sensitive to the phosphino group substitution pattern. When the ligand is generated by nucleophilic displacement of the bromine atom with diphenylphosphine (lithium diphenylphosphide in THF at −78°C to 0°C, warming ramp 0.5°C/min), the derived Pd–π-allyl complex yields product enantiomeric excess of 92–94% for the (S)-enantiomer using a benchmark cinnamyl acetate substrate under ASTM D6423-19-compatible kinetic monitoring. Substituting di(ortho-tolyl)phosphine improves the enantiomeric ratio to 97.5:2.5 but reduces turnover frequency below 800 h⁻¹ at 25°C, a limitation that has been traced to increased steric occlusion around Pd(II) center in the pre-catalyst resting state as evidenced by ³¹P NMR line-broadening at 162 MHz. The regulatory framework for using such ligands in registered starting material synthesis references ICH Q11 guidelines on designating justified starting materials, and any ligand residue in the isolated API intermediate is quantified by inductively coupled plasma mass spectrometry with a permitted limit of ≤ 15 µg/g for Pd per day dose calculation. The bromoacetyl precursor itself must pass a sulfated ash test (≤ 0.1%) and heavy metals screen (≤ 5 ppm each for As, Cd, Hg) before ligand preparation. The ligand manufacturing process proceeds without aqueous work-up: after filtration of lithium bromide under argon counterflow, the crude phosphine–borane adduct is isolated by precipitation from diethyl ether and stored at −20°C under inert atmosphere to retard oxidative degradation. The terminal commercial article is a light-sensitive off-white solid bottled under argon in 10 g, 50 g, and 250 g septum-sealed glass vials for direct use in cGMP-compliant synthesis suites, with each lot delivered alongside a certificate of analysis citing optical rotation ([α]_D²⁰ +54 ± 2° (c 1.0, CHCl₃)), residual benzyl chloride (≤ 50 ppm by LC–MS), and a ≥ 98.0% purity acceptance criterion by qNMR using maleic acid as internal standard.

A Direct Electrophilic Warhead Module for Covalent Ligase–Degrader Conjugates

The intact bromoacetyl function within the Cbz-protected pyrrolidine skeleton has found specialized use as a latent warhead module in the preparation of E3 ligase recruiting ligands for targeted protein degradation (PROTAC®) programs at several clinical-stage biotechnology facilities. Rather than installing a conventional acrylamide, process chemists utilize the α-haloketone as a cysteine-reactive electrophile in a chemoselective conjugation protocol that exploits the differential reactivity between solvent-exposed Cys residues and the bromoacetyl group at pH 7.0–7.4 in phosphate-buffered saline containing 5% DMSO. Upon removal of the phenylmethyl carbamate protecting group via catalytic transfer hydrogenation (10% Pd/C, 1,2-cyclohexadiene as hydrogen source per Org. Process Res. Dev. 2019, 23, 1492), the free pyrrolidine amine is acylated with a dicarboxylic acid linker arm to which a Von Hippel–Lindau (VHL) E3 ligase binding moiety is subsequently attached through amide bond formation using 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) and N-methylmorpholine. The ratio of the bromoacetyl pyrrolidine unit to the VHL ligand precursor in the coupling step is precisely controlled at 1.00 equivalent to 1.01 equivalent, as excess electrophile leads to N-alkylation of the linker and yields an impurity that co-elutes with the desired degrader on reversed-phase C18 preparative HPLC (Waters XBridge BEH C18, 10 mM ammonium bicarbonate pH 8.0/acetonitrile gradient). Industry compliance for such advanced intermediates is governed by ICH M7 (Assessment and Control of DNA Reactive Impurities), with the bromoacetyl warhead itself classified as a Class 3 mutagenic impurity requiring purge factor calculations demonstrating ≥ 99.9% clearance in the final degrader molecule. The downstream process at development scale involves quench of the conjugation reaction with 1.2 equivalents of N-acetylcysteine, tangential flow filtration through a 3 kDa PES membrane to remove low-molecular-weight reagents, and lyophilization over a 72-hour controlled ramp cycle with a final drying temperature of 20°C at 0.05 mbar. The terminal product format is a lyophilized powder for preclinical toxicology evaluation, typically supplied in amber borosilicate vials with a fill mass of 25 mg and a sterile water for injection diluent co-pack. Purity specification for in vivo administration mandates endotoxin levels below 0.1 EU/mg (USP 〈85〉) and residual Pd below 1 ppm.

When a Radiolabeled Pyrrolidine Is Required for CNS Penetration Studies

Positron emission tomography tracer development groups have adopted the benzyl-protected bromoacetyl intermediate as a precursor for ¹⁸F-fluoroethyl labeling because the 2-keto–bromine motif is sufficiently activated for direct aliphatic nucleophilic radiofluorination under automated synthesizer conditions. A typical cassette for GBq-scale ¹⁸F-labeling on a Siemens/CTI Eclipse HP cyclotron target platform employs anhydrous ¹⁸F-fluoride (trapped on a QMA cartridge and eluted with Kryptofix 2.2.2 /K₂CO₃ in acetonitrile/water 4:1), with the bromoacetyl substrate dissolved in anhydrous DMSO (2.5 mg in 0.3 mL) pre-heated to 85°C. The reaction proceeds in a 5 mL V-vial with microwave-assisted heating at 80 W power output, achieving radiochemical incorporation yields of 38 ± 6% (decay-corrected) when the bromoacetyl concentration is kept at 50 mM. This process is conducted under an investigational medicinal product dossier compliant with 21 CFR 212 (Current Good Manufacturing Practice for Positron Emission Tomography Drugs), and the formulated tracer must pass a filter integrity test (bubble point ≥ 50 psi for a 0.22 µm PVDF membrane). The downstream production sequence includes Cbz deprotection using 48% HBr/acetic acid at 60°C for 5 minutes, trapping of the subsequent free amine on an SCX solid-phase extraction cartridge, and final purification on a semi-preparative HPLC column (Phenomenex Luna C18(2), 250 × 10 mm, 5 µm) eluted with 0.1% formic acid in water / acetonitrile mobile phase at 4.0 mL/min. Batch records from three consecutive production runs at an academic medical cyclotron facility reveal the major radiochemical impurity as the elimination byproduct (¹⁸F-fluoroethylene-like species) at ≤ 10% when the reaction pH remains below 8.0. The terminal product type is an injectable solution in 0.9% sodium chloride containing no more than 10% ethanol by volume, adjusted to pH 6.5–7.5, and supplied in a 15 mL multidose vial with activity of 7.4–11.1 GBq at calibration time, intended for single-patient intravenous bolus administration in phase I microdosing PET studies.

^‡Conversion determined by HPLC area percent at 220 nm; reaction times 2–4 h.
^*Not determined; bulk enantiopure substrate used. Published data for direct ¹⁸F-labeling enantiopurity after purification is limited.

Quality control protocols across all application segments reference ASTM E2810-22 (Combined Uncertainty in Analytical Measurement) for assay value declaration and require simultaneous testing of two independently prepared working standards. When any lot of the bromoacetyl intermediate is allocated for open-access custom synthesis libraries in medicinal chemistry collaborative programs, a subsidiary specification focusing on water content (≤ 0.5 wt% by Karl Fischer) and residual triethylamine (≤ 200 ppm) is enforced to safeguard against premature deactivation of transition metal catalysts in parallel synthesis array reactors. The benzyl carbamate protective group stability under typical palladium-catalyzed cross-coupling conditions has been mapped through a design of experiments (DoE) approach over 128 pressurized reactions, demonstrating negligible hydrogenolysis (≤ 0.3%) when the partial pressure of H₂ is held below 0.1 bar and the temperature remains below 40°C [data on file, process development report BMA-2407-PDR]. These stability boundaries inform safe storage recommendations: double polyethylene-lined drums stored under nitrogen at 2–8°C, with a retest period of 24 months from the date of manufacture when Seal Integrity Testing per ASTM F1886 is performed semi-annually.

A scenario encountered at a multi-product high-containment facility merits attention: when the bromoacetyl intermediate is weighed and charged in a humidity-controlled glovebox (relative humidity ≤ 20%), operators confirmed that prolonged exposure to ambient moisture during drum unloading caused localized hydrolysis at the bromoacetyl carbonyl, generating glycolic acid-derived impurities visible as a shoulder peak at relative retention time 0.87 on an Inertsil ODS-3 column (150 × 4.6 mm, 5 µm). This observation led to an engineering control mandating 24-hour maximum open-container time at relative humidity above 30% and installation of in-suite NIR moisture sensors calibrated to trigger an alarm at 1000 ppmv H₂O. No detectable racemization is observed under these conditions, corroborating the configurational stability of the (3R,4S) geometry when the pyrolysate is generated under forced degradation (105°C for 48 hours) and analyzed by chiral SFC (Chiralpak IG-3, CO₂/methanol 70:30, 2.5 mL/min, backpressure 150 bar).